Tarsons Products Limited · NSE:TARSONS
Tarsons Products — Q4 FY2025 Earnings Presentation
35 slides from Tarsons Products's earnings presentation, May 29, 2025
Slide 1: Exchange filing cover letter for investor presentation
An ISO 9001 & ISO 13485 Certified Company Date: 29th May, 2025 To, To, BSE Limited (“BSE”), National Stock Exchange of India Limited (“NSE”) Corporate Relationship Department, “Exchange Plaza”, 5th Floor, 2nd Floor, New Trading Ring, Plot No. C/1, G Block, P.J. Towers, Dalal Street, Bandra-Kurla Com
Slide 2: Tarsons Products Limited Investor Presentation May 2025
TARSONS PRODUCTS LIMITED Investor Presentation May 2025 TRUST DELIVERED
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Tarsons Products Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secu
Slide 4: Q4 & FY25 Financial Highlights
Q4 & FY25 Financial Highlights
Slide 5: Q4FY25 Key Operational Highlights
Q4FY25 Key Operational Highlights Revenue (in Rs. Crs) Geography Mix Standalone Consolidated 32% 29% Standalone +7% +7% Q4FY24 Q4FY25 93 113 87 106 68% 71% 59 66 59 66 Consolidated 44% 41% Q4FY24 Q4FY25 56% 59% 47 47 28 27 Q4FY24 Q4FY25 Q4FY24 Q4FY25 Domestic Overseas ➢ In Q4FY25, revenues grew by 7
Slide 6: FY25 Key Operational Highlights
FY25 Key Operational Highlights Revenue (in Rs. Crs) Geography Mix Standalone Standalone Consolidated Standalone Standalone Consolidated +13% 392 314 277 30% 32% 214 45% FY24 FY25 FY25 10.3% 214 55% 194 70% 68% 178 83 20.3% 100 FY24 FY25 FY25 Domestic Overseas ➢ In FY25, standalone revenue grew by 1
Slide 7: Q4FY25 Key Standalone Financial Highlights
Q4FY25 Key Standalone Financial Highlights Revenue (in Rs. crs) EBITDA (in Rs. crs) Profit After Tax (in Rs. crs) Cash PAT# (in Rs. crs) +7% +9% +15% -16% 93.0 37.0 18.8 33.2 86.6 33.9 15.7 29.0 Q4FY24 Q4FY25 Q4FY24 Q4FY25 Q4FY24 Q4FY25 Q4FY24 Q4FY25 GP Margin (%) EBITDA Margin (%) PAT Margin (%) -1
Slide 8: Q4FY25 Key Consolidated Financial Highlights
Q4FY25 Key Consolidated Financial Highlights Revenue (in Rs. crs) EBITDA (in Rs. crs) Profit After Tax (in Rs. crs) Cash PAT# (in Rs. crs) +7% +22% -1% +34% 112.7 37.0 10.3 10.2 30.2 105.7 30.2 22.6 Q4FY24 Q4FY25 Q4FY24 Q4FY25 Q4FY24 Q4FY25 Q4FY24 Q4FY25 GP Margin (%) EBITDA Margin (%) PAT Margin (%
Slide 9: FY25 Key Financial Highlights
FY25 Key Financial Highlights Revenue (in Rs. crs) Adj. EBITDA*^ (in Rs. crs) Profit After Tax (in Rs. crs) Cash PAT# (in Rs. crs) Standalone Standalone Consolidated Standalone Standalone Consolidated Standalone Standalone Consolidated Standalone Standalone Consolidated +8% +8% +13% 392.4 120.0 51.2
Slide 10: Bridge between Standalone & Consolidated PAT
Bridge between Standalone & Consolidated PAT (in Rs. crs) 42.7 -8.7 -2.0 2.0 29.8 -4.2 FY25 Standalone PAT Interest Income & Interest paid to Elimination of fair PAT of Nerbe FY25 Consolidated PAT Gurantee Commission bank by subsidiary value of inventory eliminated at and Amortisation consolidation
Slide 11: Management Commentary
Management Commentary Commenting on the performance of the company Mr. Aryan Sehgal, Promoter and Whole time Director of Tarsons, said: “The life sciences industry has witnessed a significant slowdown in the past six quarters. However, we observed early signs of recovery in Q4, although we believe t
Slide 12: Q4 & FY25 Standalone Profit & Loss Statement
Q4 & FY25 Standalone Profit & Loss Statement Particulars (in Rs. Crs) Q4FY25 Q4FY24 YoY FY25 FY24 YoY Revenue from Operations 93.0 86.6 7.4% 314.2 277.3 13.3% Cost of Goods Sold 26.5 23.8 89.4 72.8 Gross Profit 66.6 62.8 6.0% 224.8 204.5 9.9% Gross Profit Margin 71.6% 72.5% -100 bps 71.5% 73.8% -220
Slide 13: Q4 & FY25 Consolidated Profit & Loss Statement
Q4 & FY25 Consolidated Profit & Loss Statement Particulars (in Rs. Crs) Q4FY25 Q4FY24 YoY FY25 FY24# YoY Revenue from Operations 112.7 105.7 6.6% 392.4 296.4 32.4% Cost of Goods Sold 37.9 33.2 129.4 82.2 Gross Profit 74.8 72.5 3.2% 263.0 214.2 22.8% Gross Profit Margin 66.4% 68.6% -220 bps 67.0% 72.
Slide 14: Consolidated Balance Sheet
Consolidated Balance Sheet Consolidated Consolidated Assets (in Rs. Crs) Equity & Liabilities (in Rs. Crs) Mar-25 Mar-24 Mar-25 Mar-24 Total Equity 630.2 612.9 Non-Current Assets 837.5 736.9 Share Capital 10.6 10.6 Property Plant & Equipment 455.1 247.8 Other Equity 619.6 602.2 CWIP 232.9 267.0 Non-
Slide 15: Abridged Consolidated Cash Flow Statement
Abridged Consolidated Cash Flow Statement Consolidated Particulars (in Rs. Crs) FY25 FY24# Net Profit Before Tax 44.8 60.8 Adjustments for: Non -Cash Items / Other Investment or Financial Items 86.2 51.8 Operating profit before working capital changes 131.0 112.5 Changes in working capital -1.0 8.6
Slide 16: About Tarsons
TRUST DELIVERED
Slide 17: Tarsons – at a Glance
Tarsons – at a Glance One of the leading Indian labware company engaged in the designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop equipment & instruments) Products used in laboratories across research organizations, academia institutes, pharm
Slide 18: Our Journey
Our Journey Established Product portfolio Commenced Pioneered the first fully manufacturing facility expansion & adding Established line for PCR production of Pipette robotic clean room expanding into depth in existing products in Jalan Tips, thereby creating a plant for manufacturing production of
Slide 19: Leading Indian Labware Supplier
Leading Indian Labware Supplier Trusted Brand for high quality Expertise in production of a wide range Ability to offer differentiated, user products in the plastic labware of labware products & amongst the friendly, reliable quality & cost-effective market with 40+ years vintage in the top 3 player
Slide 20: Our Competitive Edge
Our Competitive Edge Geographical Presence Brand & Quality Wide geographic reach through a Leading Indian supplier to the life sciences strong sales & distribution sector with strong brand recognition and network high-quality diversified products across varied customer segments. 03 04 State of Art F
Slide 21: Catering to diversified End User Industry
Catering to diversified End User Industry… Measures to strengthen customer relations Academic Institutes National Centre Indian Institute of Rain Forest KIIT Regular Feedback from Customers on quality, & Research for Biological Chemical Research Institute University 1 delivery & cost Sciences Techno
Slide 22: Our State-of-the-art Manufacturing Facilities
Our State-of-the-art Manufacturing Facilities… Key Highlights of the High Precision Manufacturing Process ✓ Vertically integrated manufacturing capabilities with design & development being carried out in-house ✓ Automated manufacturing with use of robotics & other technologies developed in collabora
Slide 23: Widespread Domestic Sales & Distribution network
…with widespread Domestic Sales & Distribution network… Comprehensive Pan-India Distribution Network Long-standing relationships with Distributors North: 17% of FY25 Domestic Sales East: 13% of FY25 Domestic Sales 42 Distributors 42 Distributors West: 29% of FY25 Domestic Sales 23 Distributors South
Slide 24: Huge underlying Export Market Potential
…with huge underlying Export Market Potential… Huge Export Opportunity Market One of the very few players to have a Global Reach ✓ As of 31st March 2025, the company sold its products to 40+ countries via 45+ distributors Demand for plasticware expected to grow at 10% CAGR for developing ✓ Export op
Slide 25: Offering Wide Range of High-Quality Products
…offering Wide Range of High-Quality Products… Our products are made from high-quality medical grade DMF registered resins which are selected to minimize additives & reduce potential leachable Consumables Reusables Others 55.5% of FY25 40.7% of FY25 3.8% of FY25 Revenues Revenues Revenues • Portfoli
Slide 26: Diversified product portfolio of Plastic Labware
…diversified product portfolio of Plastic Labware Centrifuge Sterile Media Pipette Tips Petri Dishes Cryo Vials Storage Vials Serological Pipette Tubes Bottles Consumables (55% of FY25 Sales) • Mostly used in culture Designed for use Disposable pipettes Suited to preparation Used for storage of Perf
Slide 27: Glimpse of our product portfolio & processes
Glimpse of our product portfolio & processes Video link – Click here Video link – Click here Video link – Click here Video link – Click here Video link – Click here For more information & videos please visit www.tarsons.com/video-new 26
Slide 28: Key Business Strategies
Key Business Strategies • Focus on branding & promotion to enhance visibility in the labware industry to increase brand awareness & loyalty • Manufacture New Products in the cell culture & robotic handled consumables and expand Enhance existing & expand into the import dominated markets of these pro
Slide 29: Experienced Board of Director & Managerial Team
Experienced Board of Director & Managerial Team Suresh Prabhala Sanjive Sehgal Non-Executive Nominee Director Chairman & Managing Director • Currently acting as Co-founder & Managing Partner at ADV Partners • Chairman & Managing Director of Tarsons • Investment professional with 25+ years of experie
Slide 30: Contribution towards Environmental, Social & Governance
Contribution towards Environmental, Social & Governance Clean room conditions eliminates all chances of NO litigations faced for pollution or contamination Use of Medical Grade degradation of environment over the Plastics. Products are designed to past five years Productivity optimisation with use o
Slide 31: Industry Update
DELIVERING TRUST
Slide 32: Plastic Labware Market
Plastic Labware Market Indian plastic labware market is expected to grow at 16% CAGR from 2020- Split of Global Market Size of Plastic Labware (2020) 2025 Certrifuge ▪ Centrifuge & Liquid Handling Global Laboratory Equipment Indian Laboratory Equipment ware market dominate the Laboratory Market Size
Slide 33: Rapid Shift from Glassware to Plasticware in India
Rapid Shift from Glassware to Plasticware in India Indian Laboratory Equipment Market (Breakup of Glassware and Plasticware segments) INR 10.8 bn INR 11.3 bn INR 8.4 bn Key reasons for the shift: Market Size INR 7.5 bn INR 12.2 bn INR 25.8 bn ▪ Increased Applicability: Superior ability to handle rad
Slide 34: Key Takeaways
Key Takeaways Leading Indian manufacturer of Financial profile with Historical labware with an established brand strong EBITDA margins & high & focus on high-quality products ROCE Presence in an industry with Highly automated state-of-the-art double-digit growth potential and manufacturing facilitie
Slide 35: Thank You
Thank You Tarsons Products Limited Strategic Growth Advisors Private Limited CIN: L51109WB1983PLC036510 CIN: U74140MH2010PTC204285 Mr. Santosh Agarwal – Chief Financial Officer Mr. Sagar Shroff / Mr. Tanay Shah santosh@tarsons.in sagar.shroff@sgapl.net / tanay.shah@sgapl.net +91 98205 19303 / +91 98